Analysts See $-0.69 EPS for Deciphera Pharmaceuticals, Inc. (DCPH)

August 9, 2018 - By Jack Shaw

Analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to report $-0.69 EPS on August, 14.After having $-0.66 EPS previously, Deciphera Pharmaceuticals, Inc.’s analysts see 4.55 % EPS growth. The stock increased 4.39% or $1.53 during the last trading session, reaching $36.41. About 62,065 shares traded. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company has market cap of $1.37 billion. The firm develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It currently has negative earnings. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors.

More notable recent Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) news were published by: which released: “Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results” on August 07, 2018, also with their article: “Analysis: Positioning to Benefit within Xylem, Duluth, Deciphera Pharmaceuticals, Mesabi Trust, Associated Banc-Corp …” published on July 25, 2018, published: “What Blueprint Medicines Just Said About Its Future” on August 02, 2018. More interesting news about Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) were released by: and their article: “Premarket analyst action – healthcare” published on August 07, 2018 as well as‘s news article titled: “3 Top Stocks That Aren’t on Wall Street’s Radar” with publication date: July 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.